COVID-19 Vaccine: Moderna to Seek Emergency Authorisation in US, Europe

The share price of Moderna, an American Biotechnology company, rose by 20.24 percent or $25.71 on Monday after the company announced plans to apply for US and European emergency authorisation for its COVID-19 vaccine that it claimed was 100 percent effective in preventing severe cases and 94.1 percent on the regular.

Tal Zaks, Moderna Chief Medical Officer, said “We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it.”

“We expect to be playing a major part in turning around this pandemic,” Zaks stated.

This is coming two days after the United Kingdom ordered 40 million doses of Pfizer and BioNTech COVID-19 vaccine and announced plans to commence usage as early as December 7th.